Bavarian will use own money to start RSV trials, but is still seeking a partner
After several discussions with the FDA, Bavarian Nordic has finally finished designing the study of its RSV vaccine and will start a 12,000 person phase III study in 2021.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.
Try us for 14 days
Try a trial subscription for access to our quality journalism